Together with Noel Courage, MI’s Philip Goldbach co-authored an article published in BioTechnology Focus on IP rights and considerations surrounding antibody-based assets.  As the article states: Antibodies (immunoglobulins) and other antibody-derived biologics have become a mainstay of the biotechnology industry, both here in Canada and around the world. Novel antibodies are continuously being designed, modified, expressed and purified for a number of uses, including as therapeutics, diagnostics, or research tools. As is the case with other types of life science technologies, intellectual property (IP) rights must be a key consideration for anyone creating new and innovative antibodies or antibody-based applications. This article provides a brief overview of IP issues and considerations for those engaged in antibody technologies. Read more here: ow.ly/xxYW30jG6dV